


**Additional file 3. Participants reporting solicited local symptoms during the 7-day post-vaccination period in the total vaccinated cohort**



All participants received inactivated trivalent influenza vaccine, non-adjuvanted (non-adjuvanted ≥65 years and control 18–40 years) or formulated with an adjuvant. AS03 is a squalene and  $\alpha$ -tocopherol oil-in-water emulsion-based Adjuvant System, with tocopherol content 11.86 mg (A), 5.93 mg (B), or 2.97 mg (C); MPL is 3-O-desacyl-4'-monophosphoryl lipid A: 25  $\mu$ g (MPL-25) or 50  $\mu$ g (MPL-50).